Compare Barrick Gold Corp (B) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs Crispr Therapeutics AG — how do they compare? Barrick Gold Corp trades at $36.1 (market cap $60.50B), while Crispr Therapeutics AG trades at $50.91 (market cap $4.97B). The key difference: Barrick Gold Corp is far larger — about 12.2× Crispr Therapeutics AG's market cap, and Barrick Gold Corp pays a 1.92% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| B | CRSP | |
|---|---|---|
Market Cap | $60.50B | $4.97B |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $76.78 |
52-Week Low | $20.73 | $44.34 |
Enterprise Value | $58.09B | $3.32B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $35.94, down 2.02% today, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and three consecutive quarterly EPS beats. Recent cash flow trends improved significantly, with 2025 net cash flow turning positive at $2.63 billion. The company announced a $0.18 dividend payable in June 2026.
The outlook remains positive given low valuation multiples, robust profitability, and analyst consensus of $52.67 price target. Key risks include gold price volatility and execution of growth projects. With 68% analyst buy ratings and no sell recommendations, Wall Street sentiment supports long-term upside potential despite near-term technical weakness.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
